Latest Neurizon Therapeutics (ASX:NUZ) News
Page 2
Page 2 of 6
Neurizon Cuts Convertible Note Exposure in US$1.15 Million Obsidian Deal
10 Sept 2026
NIH grant opens expanded access pathway for Neurizon’s NUZ-001 ALS therapy
9 Sept 2026
Neurizon Names Global Pharma Executive Chris Bremer as CEO Ahead of ALS Results
7 Sept 2026
Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026
29 Aug 2026
Neurizon Therapeutics Advances ALS Trial and Strengthens Financial Position in FY2026
25 Aug 2026
Market Wrap - Week 29 (13 July -> 17 July) 2026
18 July 2026
Healthcare Wrap - Week 29 (13 July -> 17 July) 2026
18 July 2026
Neurizon Accelerates ALS Trial Results After Fastest Ever HEALEY Enrolment
17 July 2026
Healthcare Wrap - Week 25 (15 June -> 19 June) 2026
20 June 2026
Neurizon Locks in Five-Year Supply Deal with Elanco to Boost NUZ-001 Commercialisation
17 June 2026
Healthcare Wrap - Week 24 (8 June -> 12 June) 2026
13 June 2026
Neurizon Passes Halfway Mark in Expanded HEALEY ALS Trial Ahead of Schedule
12 June 2026